Agreements reached under this partnership
Capital and Business Alliance- 1
Target diseases: All ophthalmic diseases, including glaucoma
- 2
Territory: Japan, China (including Hong Kong, Macao and Taiwan), South Korea, ASEAN member states and certain other regions
- 3
Rights: Right to transition to a license agreement for H-1337
- 4
Right of first refusal: The Company will grant 千寿製薬 a right of first refusal in countries and regions outside the territory
- 5
Role — the Company: Conduct Phase III clinical trials for H-1337 in Japan
- 6
Role — 千寿製薬: Support the Company's clinical trials
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
If the option is exercised, the Company will receive up to ¥1.85 billion in total upfront and development milestone payments, up to ¥4.15 billion in total sales milestone payments, and royalties based on sales at a rate of up to a double-digit percentage. Timing of achievement: not disclosed.
This indicates whether the companies will do more than work together, such as holding each other’s shares or seconding personnel (capital and business alliance).
The specific impact on results for the fiscal year ending December 2026 is immaterial at this time.
| Item | Details |
|---|---|
| Name of alliance partner | 千寿製薬株式会社 |
| Alliance partner's business activities | Pharmaceuticals, medical devices and other businesses |
| Alliance partner's location | 3-1-9 Kawaramachi, Chuo-ku, Osaka, Japan |
| Alliance partner's capital | ¥1,415 million |
| Alliance partner's net sales | ¥48,917 million (fiscal year ended March 2025) |
| Alliance partner's operating income | ¥2,423 million (fiscal year ended March 2025) |
| Type of alliance | Capital and Business Alliance |
| Details of the alliance | Target diseases: All ophthalmic diseases, including glaucoma, Territory: Japan, China (including Hong Kong, Macao and Taiwan), South Korea, ASEAN member states and certain other regions, Rights: Right to transition to a license agreement for H-1337, Right of first refusal: The Company will grant 千寿製薬 a right of first refusal in countries and regions outside the territory, Role — the Company: Conduct Phase III clinical trials for H-1337 in Japan, Role — 千寿製薬: Support the Company's clinical trials |
| Number of shares acquired | 2,150,500 shares (3.96% of the total number of shares issued as of 31 December 2025, excluding treasury shares) |
| Acquisition price | ¥199,996,500 |
| Shareholding ratio | 0% (before the alliance) → 3.96％（3.96％） |
| Numerical targets under the alliance | If the option is exercised, the Company will receive up to ¥1.85 billion in total upfront and development milestone payments, up to ¥4.15 billion in total sales milestone payments, and royalties based on sales at a rate of up to a double-digit percentage. Timing of achievement: not disclosed. |
| Shareholding Policy | 千寿製薬 intends to hold the Company's shares over the long term. For six months from the payment date, it will not transfer the shares to a third party, provide them as collateral or otherwise dispose of them without approval based on a prior resolution of the Company's Board of Directors. If it transfers the shares within two years of the payment date, it will provide the Company with a written report and make other required disclosures. |
| Date of board resolution | 25 March 2026 |
| Contract Date | 25 March 2026 |
| Alliance start date | 10 April 2026 (予定) |
| Share Acquisition Date and Payment Date | 10 April 2026 |
| Impact on Business Performance | The specific impact on results for the fiscal year ending December 2026 is immaterial at this time. |
| Change in major shareholders | Hidaka Yuichi (日高 有一): 9.49% (before the offering) → Hidaka Yuichi (日高 有一): 9.13% (after the offering). 千寿製薬株式会社: 3.81% (after the offering)（Hidaka Yuichi (日高 有一): decrease of 0.36 percentage points） |
Items this document does not state (4)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To prioritize the development of H-1337 in Japan and accelerate its launch with support from 千寿製薬. The proceeds will also be used to fund development costs for H-1337 and enhance the product's business value.